Ausgabe 6/2020
Inhalt (14 Artikel)
Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function
Yanke Yu, Justin Hoffman, Anna Plotka, Melissa O’Gorman, Haihong Shi, Diane Wang
Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation
Senthil Velan Bhoopalan, Shane J. Cross, John C. Panetta, Brandon M. Triplett
Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration
Sufeng Zhou, Wei Liu, Chen Zhou, Lingling Zhang, Lijun Xie, Zhaoqiang Xu, Lu Wang, Yuqing Zhao, Lian Guo, Juan Chen, Lieming Ding, Li Mao, Yi Tao, Chen Zhang, Sijia Ding, Feng Shao
The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis
Chen Ye, Abuduhaibaier Sadula, Siqian Ren, Xin Guo, Meng Yuan, Chunhui Yuan, Dianrong Xiu
Urine NGAL and KIM-1: tubular injury markers in acute lymphoblastic leukemia survivors
Eryk Latoch, Katarzyna Konończuk, Katarzyna Taranta-Janusz, Katarzyna Muszyńska-Rosłan, Edyta Szymczak, Anna Wasilewska, Maryna Krawczuk-Rybak
Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients
Mads Kingo Guldberg Hansen, Maja Patricia Smerdel, Marianne Waldstrøm, Rikke Fredslund Andersen, Parvin Adimi, Anders Jakobsen, Karina Dahl Steffensen
Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer
Zhen Zhang, Luoyan Zhang, Guoxiang Yu, Zhigang Sun, Tiantian Wang, Xingsong Tian, Xuening Duan, Chi Zhang
Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma
Xiang-Rong Ni, Cheng-Cheng Guo, Yan-Jiao Yu, Zhi-Hui Yu, Hai-Ping Cai, Wei-Chi Wu, Jun-Xiao Ma, Fu-Rong Chen, Jing Wang, Zhong-Ping Chen
The biologically functional identification of a novel TIM3-binding peptide P26 in vitro and in vivo
Tangwu Zhong, Chuanke Zhao, Shuntao Wang, Deshuang Tao, Shuxia Ma, Chengchao Shou
Bioequivalence study of 20-mg and 100-mg temozolomide capsules (TOZ309 and Temodal®) in glioma patients in China
Chaoying Hu, Qingtang Lin, Chuan Liu, Jacqueline Liu, Xiaobao Chen, Xinxia Li, Guoguang Zhao, Lan Zhang
Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma
Kojiro Hata, Kimitaka Suetsugu, Nobuaki Egashira, Yoko Makihara, Shinji Itoh, Tomoharu Yoshizumi, Masatake Tanaka, Motoyuki Kohjima, Hiroyuki Watanabe, Satohiro Masuda, Ichiro Ieiri
Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors
Khanh T. Do, Geraldine O’Sullivan Coyne, John L. Hays, Jeffrey G. Supko, Stephen V. Liu, Kristin Beebe, Len Neckers, Jane B. Trepel, Min-Jung Lee, Tomoko Smyth, Courtney Gannon, Jennifer Hedglin, Alona Muzikansky, Susana Campos, John Lyons, Percy Ivy, James H. Doroshow, Alice P. Chen, Geoffrey I. Shapiro
Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children’s Oncology Group phase 1 consortium study (ADVL1212)
Emily Greengard, Yael P. Mosse, Xiaowei Liu, Charles G. Minard, Joel M. Reid, Stephan Voss, Keith Wilner, Elizabeth Fox, Frank Balis, Susan M. Blaney, Peter C. Adamson, Brenda J. Weigel
All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma
Maria Christina Cox, Marta Banchi, Sabrina Pelliccia, Arianna Di Napoli, Luigi Marcheselli, Caterina Patti, Paola Anticoli Borza, Roberta Battistini, Francesca Di Gregorio, Paola Orlandi, Guido Bocci